JP2023515101A - 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法 - Google Patents

神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法 Download PDF

Info

Publication number
JP2023515101A
JP2023515101A JP2022550119A JP2022550119A JP2023515101A JP 2023515101 A JP2023515101 A JP 2023515101A JP 2022550119 A JP2022550119 A JP 2022550119A JP 2022550119 A JP2022550119 A JP 2022550119A JP 2023515101 A JP2023515101 A JP 2023515101A
Authority
JP
Japan
Prior art keywords
compound
alkyl
disease
administration
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022550119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515101A5 (enExample
Inventor
ニコラス トーマス ハーツ
ダラ ディツワース
ヨアン バルトロメウス
ショーン ジョンストーン
ランドル マルセロ チン
ロバート デビータ
フィリップ マクギー
ジュリアン ダンスロー
リシ ラヒト
Original Assignee
ミトキニン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミトキニン インコーポレイテッド filed Critical ミトキニン インコーポレイテッド
Publication of JP2023515101A publication Critical patent/JP2023515101A/ja
Publication of JP2023515101A5 publication Critical patent/JP2023515101A5/ja
Priority to JP2025078577A priority Critical patent/JP7808226B2/ja
Priority to JP2026005770A priority patent/JP2026067907A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022550119A 2020-02-21 2021-02-22 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法 Withdrawn JP2023515101A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025078577A JP7808226B2 (ja) 2020-02-21 2025-05-09 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
JP2026005770A JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980143P 2020-02-21 2020-02-21
US62/980,143 2020-02-21
PCT/US2021/019113 WO2021168446A1 (en) 2020-02-21 2021-02-22 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078577A Division JP7808226B2 (ja) 2020-02-21 2025-05-09 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Publications (2)

Publication Number Publication Date
JP2023515101A true JP2023515101A (ja) 2023-04-12
JP2023515101A5 JP2023515101A5 (enExample) 2024-09-18

Family

ID=77391353

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022550119A Withdrawn JP2023515101A (ja) 2020-02-21 2021-02-22 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
JP2025078577A Active JP7808226B2 (ja) 2020-02-21 2025-05-09 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
JP2026005770A Pending JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025078577A Active JP7808226B2 (ja) 2020-02-21 2025-05-09 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
JP2026005770A Pending JP2026067907A (ja) 2020-02-21 2026-01-16 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法

Country Status (16)

Country Link
US (1) US20240018146A1 (enExample)
EP (1) EP4106874A4 (enExample)
JP (3) JP2023515101A (enExample)
KR (2) KR20220158290A (enExample)
CN (1) CN115515682B (enExample)
AU (1) AU2021222053A1 (enExample)
BR (1) BR112022016614A2 (enExample)
CA (1) CA3168531A1 (enExample)
CO (1) CO2022013603A2 (enExample)
CR (1) CR20220476A (enExample)
EC (1) ECSP22074210A (enExample)
IL (2) IL326926A (enExample)
MX (2) MX2022010309A (enExample)
PH (1) PH12022552518A1 (enExample)
WO (1) WO2021168446A1 (enExample)
ZA (1) ZA202210409B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947390A4 (en) * 2019-04-03 2022-11-30 Mitokinin, Inc. COMPOSITIONS AND METHODS FOR THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
CN119752781B (zh) * 2025-03-04 2025-07-01 中国农业大学 缓解成熟卵子老化的组合物、培养液、产品及方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09323995A (ja) * 1996-02-29 1997-12-16 Farmacia & Upjohn Spa チロシンキナーゼ阻害剤としての４−置換ピロロピリミジン化合物
US7183270B2 (en) * 2003-02-12 2007-02-27 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2009528986A (ja) * 2006-02-02 2009-08-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｅ１活性化酵素の阻害剤
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2342178B1 (en) * 2008-09-02 2016-09-28 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09323995A (ja) * 1996-02-29 1997-12-16 Farmacia & Upjohn Spa チロシンキナーゼ阻害剤としての４−置換ピロロピリミジン化合物
US7183270B2 (en) * 2003-02-12 2007-02-27 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2009528986A (ja) * 2006-02-02 2009-08-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｅ１活性化酵素の阻害剤
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Also Published As

Publication number Publication date
WO2021168446A1 (en) 2021-08-26
IL295681B2 (en) 2026-08-01
EP4106874A4 (en) 2024-03-20
MX2022010309A (es) 2022-11-14
CN115515682B (zh) 2024-06-21
IL295681A (en) 2022-10-01
JP7808226B2 (ja) 2026-01-28
PH12022552518A1 (en) 2024-03-11
CN115515682A (zh) 2022-12-23
JP2026067907A (ja) 2026-04-21
JP2025142197A (ja) 2025-09-30
IL326926A (en) 2026-05-01
CO2022013603A2 (es) 2023-03-17
BR112022016614A2 (pt) 2022-12-13
IL295681B1 (en) 2026-04-01
EP4106874A1 (en) 2022-12-28
KR20220158290A (ko) 2022-11-30
CA3168531A1 (en) 2021-08-26
CR20220476A (es) 2023-05-31
KR20260098022A (ko) 2026-06-25
US20240018146A1 (en) 2024-01-18
AU2021222053A1 (en) 2022-09-15
MX2026003961A (es) 2026-05-04
ZA202210409B (en) 2024-01-31
ECSP22074210A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
JP7299837B2 (ja) 化合物、組成物、および使用方法
AU2016256917B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
JP7808226B2 (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
KR20210107046A (ko) 거대고리 화합물 및 질환 치료에서 이들의 용도
CN102369202A (zh) 氮杂喹啉酮衍生物及其应用
US9809568B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3291810B1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US20250250276A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
CN104337812B (zh) 取代的杂芳基化合物及其使用方法和用途
CA3134491A1 (en) Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
US20250129080A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
US12398156B2 (en) Compounds for prevention or treatment of neurodegenerative disorders
WO2024040266A2 (en) Disubstituted benzoimidazole and indole analogs as modulators of pink1
US20240376111A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2022072925A1 (en) Compositions and methods of treating kidney disease and fibrosis
BR122025016812A2 (pt) Compostos de adeninas, uso dos mesmos, composição farmacêutica, método para modular a atividade da quinase pink1 em um indivíduo, e kit
HK40086209B (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
HK40086209A (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2024040267A2 (en) Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
WO2023067388A1 (en) Uses of cftr modulator and/or pde4 inhibitor compounds
EA046811B1 (ru) Соединения, являющиеся ингибиторами oga
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1177199A (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250306

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250410

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250513